Literature DB >> 17205535

Association of acquired von Willebrand syndrome with AL amyloidosis.

Cynthia A Kos1, Jennifer E Ward, Karim Malek, Vaishali Sanchorawala, Daniel G Wright, Carl O'Hara, Lawreen Connors, Martha Skinner, David C Seldin.   

Abstract

Acquired loss of functional von Willebrand factor (VWF) has been termed the acquired von Willebrand syndrome (AVWS). AVWS is a rare adult-onset bleeding diathesis that is clinically similar to congenital von Willebrand disease (VWD), and occurs with a variety of autoimmune, lymphoproliferative, or myeloproliferative disorders. We have identified four patients with AVWS in association with immunoglobulin light chain (AL) amyloidosis. These patients, lacking any pre-existing or family history of abnormal bleeding, developed cutaneous, mucosal, or gastrointestinal bleeding in the course of their disease without deficiency of clotting factor X or other factors; the activated partial thromboplastin time (aPTT) was prolonged in three out of the four cases. Despite normal VWF antigen levels, VWF ristocetin cofactor activity (VWF:RCo) was low. Electrophoresis patterns of high molecular weight (HMW) VWF multimers were abnormal in two of the four cases. Two of the patients were treated with high-dose intravenous melphalan followed by autologous stem cell transplantation (HDM/SCT) and achieved hematologic remission. In these two patients, the bleeding diathesis improved and the coagulation parameters normalized, confirming a causal relationship between the plasma cell dyscrasia and the AVWS. AVWS should be considered in AL amyloidosis patients with hemorrhagic diatheses and normal clotting factor levels. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205535     DOI: 10.1002/ajh.20829

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

Review 1.  [Hereditary and non-hereditary cutaneous amyloidoses].

Authors:  S Schreml; J Schroeder; F Eder; R M Szeimies; M Landthaler; P Babilas
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

2.  Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Authors:  Katherine M Bever; Luke I Masha; Fangui Sun; Lauren Stern; Andrea Havasi; John L Berk; Vaishali Sanchorawala; David C Seldin; J Mark Sloan
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

3.  Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.

Authors:  Masahisa Arahata; Hiroyuki Takamatsu; Eriko Morishita; Yasuko Kadohira; Shinya Yamada; Akitada Ichinose; Hidesaku Asakura
Journal:  Int J Hematol       Date:  2020-01-03       Impact factor: 2.490

4.  Acquired von Willebrand Syndrome Associated to Secondary IgM MGUS Emerging after Autologous Stem Cell Transplantation for AL Amyloidosis.

Authors:  Hina Qamar; Adrienne Lee; Karen Valentine; Leslie Skeith; Victor H Jimenez-Zepeda
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-05-01       Impact factor: 2.576

5.  Portal Hypertension and a Stiff Liver.

Authors:  Felicia D'Alitto; Amina Scherz; Cristina Margini; Hendrik Von Tengg-Kobligk; Matteo Montani; Thomas Pabst; Annalisa Berzigotti
Journal:  Cureus       Date:  2018-06-08

Review 6.  Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

Authors:  Efstathios Kastritis; Ashutosh Wechalekar; Stefan Schönland; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Monique Minnema; Murielle Roussel; Arnaud Jaccard; Ute Hegenbart; Shaji Kumar; Maria T Cibeira; Joan Blade; Meletios A Dimopoulos
Journal:  Br J Haematol       Date:  2020-07-04       Impact factor: 8.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.